Intracellular Historical Cash Flow

ITCI Stock  USD 86.03  0.38  0.44%   
Analysis of Intracellular cash flow over time is an excellent tool to project Intracellular Th future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change To Liabilities of 15 M or Stock Based Compensation of 55.5 M as it is a great indicator of Intracellular ability to facilitate future growth, repay debt on time or pay out dividends.
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Intracellular Th latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Intracellular Th is a good buy for the upcoming year.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Intracellular Th. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

About Intracellular Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Intracellular balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Intracellular's non-liquid assets can be easily converted into cash.

Intracellular Cash Flow Chart

As of now, Intracellular's Stock Based Compensation is increasing as compared to previous years. The Intracellular's current Begin Period Cash Flow is estimated to increase to about 157.9 M, while Total Cash From Operating Activities is projected to decrease to (130.4 M).

Capital Expenditures

Capital Expenditures are funds used by Intracellular Th to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Intracellular operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.
Most accounts from Intracellular's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Intracellular Th current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Intracellular Th. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
As of now, Intracellular's Stock Based Compensation is increasing as compared to previous years. The Intracellular's current Begin Period Cash Flow is estimated to increase to about 157.9 M, while Total Cash From Operating Activities is projected to decrease to (130.4 M).

Intracellular cash flow statement Correlations

-0.540.43-0.02-0.410.190.41-0.53-0.360.350.530.29-0.380.41-0.22-0.33-0.020.04-0.130.43-0.18
-0.54-0.67-0.230.4-0.19-0.730.980.5-0.6-0.920.10.58-0.47-0.010.530.12-0.10.45-0.740.01
0.43-0.670.46-0.820.370.94-0.65-0.690.860.78-0.12-0.90.590.24-0.91-0.650.680.070.940.49
-0.02-0.230.46-0.490.20.51-0.16-0.150.370.31-0.33-0.590.130.4-0.61-0.480.50.190.520.79
-0.410.4-0.82-0.490.0-0.830.410.7-0.87-0.580.180.84-0.760.020.880.76-0.55-0.02-0.84-0.39
0.19-0.190.370.20.00.12-0.17-0.06-0.170.24-0.22-0.31-0.40.58-0.240.150.680.250.130.5
0.41-0.730.940.51-0.830.12-0.71-0.690.930.82-0.05-0.870.670.2-0.9-0.710.54-0.071.00.42
-0.530.98-0.65-0.160.41-0.17-0.710.62-0.59-0.920.090.62-0.520.080.560.08-0.080.48-0.720.06
-0.360.5-0.69-0.150.7-0.06-0.690.62-0.7-0.61-0.040.84-0.780.320.810.39-0.330.08-0.7-0.12
0.35-0.60.860.37-0.87-0.170.93-0.59-0.70.69-0.01-0.780.85-0.07-0.83-0.770.35-0.070.930.24
0.53-0.920.780.31-0.580.240.82-0.92-0.610.69-0.12-0.740.510.08-0.7-0.220.29-0.260.830.18
0.290.1-0.12-0.330.18-0.22-0.050.09-0.04-0.01-0.120.160.06-0.190.150.05-0.240.07-0.07-0.29
-0.380.58-0.9-0.590.84-0.31-0.870.620.84-0.78-0.740.16-0.63-0.090.990.56-0.64-0.11-0.89-0.56
0.41-0.470.590.13-0.76-0.40.67-0.52-0.780.850.510.06-0.63-0.57-0.65-0.52-0.02-0.210.68-0.13
-0.22-0.010.240.40.020.580.20.080.32-0.070.08-0.19-0.09-0.57-0.13-0.240.690.250.170.68
-0.330.53-0.91-0.610.88-0.24-0.90.560.81-0.83-0.70.150.99-0.65-0.130.67-0.67-0.13-0.91-0.59
-0.020.12-0.65-0.480.760.15-0.710.080.39-0.77-0.220.050.56-0.52-0.240.67-0.55-0.18-0.69-0.5
0.04-0.10.680.5-0.550.680.54-0.08-0.330.350.29-0.24-0.64-0.020.69-0.67-0.550.380.530.81
-0.130.450.070.19-0.020.25-0.070.480.08-0.07-0.260.07-0.11-0.210.25-0.13-0.180.38-0.050.6
0.43-0.740.940.52-0.840.131.0-0.72-0.70.930.83-0.07-0.890.680.17-0.91-0.690.53-0.050.42
-0.180.010.490.79-0.390.50.420.06-0.120.240.18-0.29-0.56-0.130.68-0.59-0.50.810.60.42
Click cells to compare fundamentals

Intracellular Account Relationship Matchups

Intracellular cash flow statement Accounts

201920202021202220232024 (projected)
Capital Expenditures700.4K266.7K325.7K778K269K377.9K
Total Cash From Operating Activities(128.0M)(230.1M)(259.5M)(270.2M)(124.2M)(130.4M)
Net Income(147.7M)(227.0M)(284.1M)(256.3M)(139.7M)(146.7M)
End Period Cash Flow107.6M61.4M93.8M150.4M149.5M157.0M
Change To Liabilities(3.2M)(1.7M)3.2M12.4M14.2M15.0M
Change In Cash52.7M(46.2M)32.3M56.6M(848K)(805.6K)
Stock Based Compensation20.8M24.1M34.3M43.0M52.8M55.5M
Free Cash Flow(128.7M)(230.3M)(259.9M)(271.0M)(124.5M)(130.7M)
Change In Working Capital(589.5K)(27.3M)(6.4M)(58.1M)(29.6M)(28.1M)
Begin Period Cash Flow54.9M107.6M61.4M93.8M150.4M157.9M
Total Cashflows From Investing Activities177.4M(480.3M)280.3M(128.4M)(147.6M)(140.2M)
Other Cashflows From Financing Activities3.2M11.5M11.5M21.4M17.8M30.9M
Depreciation477.1K528.1K533.4K656K528K342.7K
Other Non Cash Items194.2K214.1K178.5K537K(8.3M)(7.9M)
Total Cash From Financing Activities3.2M664.2M11.5M455.2M17.8M16.9M
Sale Purchase Of Stock3.2M664.2M11.5M455.2M523.4M549.6M
Investments178.1M(480.0M)280.7M(127.6M)105.5M110.8M
Cash And Cash Equivalents Changes52.7M(46.2M)32.3M56.6M65.1M68.3M
Cash Flows Other Operating2.4M(8.0M)(11.4M)482K433.8K455.5K
Change To Netincome21.2M24.6M30.4M43.1M49.6M52.0M
Change To Operating Activities5.7M(7.8M)740.8K11.2M12.8M13.5M

Currently Active Assets on Macroaxis

When determining whether Intracellular Th offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Intracellular's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Intracellular Th Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Intracellular Th Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Intracellular Th. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intracellular. If investors know Intracellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intracellular listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.87)
Revenue Per Share
6.096
Quarterly Revenue Growth
0.39
Return On Assets
(0.07)
Return On Equity
(0.1)
The market value of Intracellular Th is measured differently than its book value, which is the value of Intracellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intracellular's value that differs from its market value or its book value, called intrinsic value, which is Intracellular's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intracellular's market value can be influenced by many factors that don't directly affect Intracellular's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intracellular's value and its price as these two are different measures arrived at by different means. Investors typically determine if Intracellular is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intracellular's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.